Site-Specific Antibody Conjugation for ADC and Beyond

Area of Science:

• Biotechnology
• Oncology
• Medicinal Chemistry

Background:

• Antibody-drug conjugates (ADCs) are a key class of antitumor agents, with several approved for cancer therapy.
• Conventional conjugation methods yield heterogeneous ADCs, limiting therapeutic potential.
• Site-specific conjugation offers a strategy to overcome heterogeneity and improve ADC properties.

Purpose of the Study:

• To review advancements in site-specific conjugation technologies for antibody-drug conjugates.
• To highlight the benefits of site-specific conjugation in producing homogeneous ADCs.
• To explore emerging applications of site-specific conjugation beyond traditional ADCs.

Main Methods:

• Development of site-specific conjugation techniques targeting defined sites on antibodies (e.g., cysteine, glycans, unnatural amino acids).
• Application of these methods to couple cytotoxic drugs and other payloads to antibodies.
• Evaluation of the resulting immunoconjugates for homogeneity, therapeutic index, and antitumor activity.

Main Results:

• Site-specific conjugation yields highly homogeneous ADCs with enhanced therapeutic indices and potent in vitro/in vivo antitumor activity.
• These technologies enable the creation of diverse immunoconjugates, including bispecific antibodies and antibody-antibiotic conjugates.
• Advancements extend beyond cytotoxin payloads to include other chemicals and small proteins.

Conclusions:

• Site-specific conjugation represents a significant improvement over conventional methods for generating antibody-based therapeutics.
• The versatility of these technologies facilitates the development of next-generation immunoconjugates for treating various challenging diseases.
• Future research is expected to yield further innovations in site-specific conjugation and its applications.